Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
-
Publication number: 20080124330Abstract: An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.Type: ApplicationFiled: October 26, 2005Publication date: May 29, 2008Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Kiyotaka Nakano, Izumi Sugo, Masamichi Sugimoto, Takahiro Ishiguro, Megumi Tanaka, Shigeyuki Iijima
-
Publication number: 20080108133Abstract: A purified polypeptide that binds to neoplastic cells, which may be an antibody, is produced by the hybridoma SAM-6, a method for its production and use in the treatment and diagnosis of neoplasms.Type: ApplicationFiled: November 12, 2004Publication date: May 8, 2008Inventors: Heinz Vollmers, Hans-Konrad Muller-Hermelink
-
Publication number: 20080107662Abstract: The invention discloses alternative splice variants in Philadelphia chromosome positive leukemia, immunogenic peptides and proteins thereby produced and the use thereof in the preparation of antitumor agents.Type: ApplicationFiled: July 15, 2005Publication date: May 8, 2008Inventors: Vito Michele Fazio, Gisella Volpe, Giuseppe Saglio
-
Publication number: 20080107596Abstract: The present invention provides new markers and methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating breast cancer.Type: ApplicationFiled: May 23, 2007Publication date: May 8, 2008Inventors: Susana Salceda, Robert Cafferkey, Herve Recipon, Yongming Sun
-
Patent number: 7361511Abstract: The invention relates to nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are also provided.Type: GrantFiled: August 20, 2003Date of Patent: April 22, 2008Assignee: Millenium Pharmaceuticals, Inc.Inventors: John E. Monahan, Xumei Zhao, Yan Chen
-
Patent number: 7355008Abstract: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: January 9, 2004Date of Patent: April 8, 2008Assignee: Macrogenics, Inc.Inventors: Jeffrey Stavenhagen, Sujata Vijh, Christopher Rankin, Sergey Gorlatov, Ling Huang
-
Patent number: 7355011Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.Type: GrantFiled: May 2, 2003Date of Patent: April 8, 2008Assignee: UCB Pharma S.A.Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
-
Patent number: 7355013Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: July 1, 2002Date of Patent: April 8, 2008Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
-
Patent number: 7351583Abstract: A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein are described. PHOR-1 is a G protein-coupled receptor with homology to receptors involved in olfaction. PHOR-1 in normal human tissues is restricted to prostate, and this gene is highly over-expressed in prostate cancer as well as in cancers of the kidney, uterus, cervix, stomach and rectum. Consequently, PHOR-1 provides a diagnostic and/or therapeutic target for prostate cancer.Type: GrantFiled: November 16, 2004Date of Patent: April 1, 2008Assignee: Agensys, Inc.Inventors: Arthur B. Raitano, Daniel E. H. Afar, Aya Jakobovits, Mary Faris, Rene S. Hubert, Steven Chappell Mitchell, Douglas Saffran
-
Publication number: 20080050377Abstract: The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.Type: ApplicationFiled: April 16, 2004Publication date: February 28, 2008Applicant: GENENTECH, INC.Inventors: Heidi Ackerly, Avi Ashkenazi, David Eberhard, Gretchen Frantz, Dorothy French, Germaine G. Fuh, Jo-Anne S. Hongo, Chingwei V. Lee, Scot A. Marsters, Helga A. Raab, Evgeny Varfolomeev, Beni B. Wolf, Robert Maurice Pitti, Liliana Soroceanu
-
Patent number: 7335467Abstract: The invention provides methods for diagnosing cancer including breast cancer, based on the identification of certain breast cancer-associated polypeptides as antigens that elicit immune responses in breast cancer. The identified antigens can be utilized as markers for diagnosing breast cancer, and for following the course of treatment of breast cancer.Type: GrantFiled: May 15, 2002Date of Patent: February 26, 2008Assignees: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc., Memorial Sloan-Kettering Cancer CenterInventors: Matthew J. Scanlan, Ivan Gout, Elisabeth Stockert, Lloyd J. Old, Ali Gure, Yao-Tseng Chen
-
Patent number: 7335744Abstract: This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.Type: GrantFiled: December 21, 2004Date of Patent: February 26, 2008Assignee: The Regents of the California UniversityInventors: Bin Liu, James D. Marks
-
Patent number: 7335747Abstract: Myc protein is an unevenly distributed intermediate agent for cell proliferation, and activates a gene expression via E.box. Mina53 gene encodes a protein of 53 kDa molecular weight and is present in the nucleoplasm and nucleolus. Mina53 mRNA and protein expression are induced by artificial introduction of c-Myc activity. E.box site is present in the vicinity of the transcription initiation site of mina53 gene, and the expression from mina53 promoter is activated by c-Myc through the medium of E.box. Specific inhibition of mina53 expression in HeLa cells and rat fibroblast cells 3Y1 having high expression c.myc strikingly inhibits cell proliferation. The combination of these results show that mina53 is a Myc target gene and is associated with cell proliferation in mammals.Type: GrantFiled: April 14, 2003Date of Patent: February 26, 2008Assignee: Gakkouhoujin Kurume UniversityInventors: Makoto Tsuneoka, Hiroshi Kimura
-
Patent number: 7329502Abstract: It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein.Type: GrantFiled: December 3, 2002Date of Patent: February 12, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Louis M. Staudt, Andreas Rosenwald, Wyndham Wilson, Todd S. Barry, Adrian Wiestner
-
Patent number: 7312318Abstract: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.Type: GrantFiled: March 3, 2003Date of Patent: December 25, 2007Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
-
Patent number: 7306926Abstract: The present invention relates to a method for the early diagnosis of carcinomas and their preliminary stages, which comprises determining the overexpression of a cell cycle regulatory protein in a solubilized body sample. The present invention is particularly directed to a method for detecting cervical carcinomas, cervical intraepithelial neoplasias, or cervical carcinomas in-situ from a solubilized cervical body sample of a human subject, by solubilizing the cervical body sample in a lysis buffer, and determining the overexpression of cyclin dependent kinase inhibitor p16 in the solubilized cervical sample. The invention also concerns a test kit usable for this purpose as well as an in-vitro diagnostic device.Type: GrantFiled: August 26, 2003Date of Patent: December 11, 2007Assignee: MTM Laboratories AGInventors: Magnus Von Knebel Doeberitz, RĂ¼diger Ridder, Matthias Herkert, Anja Reichert
-
Patent number: 7306801Abstract: Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.Type: GrantFiled: May 14, 2001Date of Patent: December 11, 2007Assignees: Health Research, Inc., ARCH DevelopmentInventors: Michael A. Caligiuri, Neal J. Meropol, Richard L. Schilsky
-
Patent number: 7297776Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: June 26, 2002Date of Patent: November 20, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
-
Patent number: 7294701Abstract: An antibody fragment and methods of utilizing same are provided. The antibody fragment includes an antigen binding region capable of binding an extracellular portion of a P-glycoprotein thereby at least partially inhibiting drug efflux activity in multidrug resistant cells.Type: GrantFiled: April 2, 2003Date of Patent: November 13, 2007Assignee: Technion Research & Development Foundation Ltd.Inventors: Yoram Reiter, Maya Haus-Cohen
-
Patent number: 7291717Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 9, 2002Date of Patent: November 6, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
-
Patent number: 7288252Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: October 2, 2001Date of Patent: October 30, 2007Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 7288637Abstract: More than 90% of mutations found in the p53 protein produce a conformational change in p53 which results in the exposure of an epitope, which is otherwise hidden in the hydrophobic core of the molecule. A single chain antibody (scFv) which specifically recognizes this common mutant epitope in mutant p53 but not in wild type p53 is disclosed. Also described are a DNA molecule encoding the scFv, pharmaceutical compositions comprising the antibody and methods of treatment using the pharmaceutical compositions.Type: GrantFiled: September 20, 2002Date of Patent: October 30, 2007Assignee: Ramot At Tel Aviv University Ltd.Inventors: Beka Solomon, Gerald Cohen, Dimitri Govorko
-
Patent number: 7288636Abstract: Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer.Type: GrantFiled: February 23, 2001Date of Patent: October 30, 2007Assignee: Hybritech IncorporatedInventors: Stephen D. Mikolajczyk, Harry G. Rittenhouse, Abhay Kumar, Mohammad S. Saedi, Robert L. Wolfert
-
Patent number: 7288249Abstract: The present application describes a method for making antibodies which can be used for cancer diagnosis or therapy. The application also discloses a method for identifying an antigen which is differentially expressed on the surface of two or more distinct cell populations. The application additionally describes human antibodies directed against decay accelerating factor (DAF), as well as therapeutic compositions comprising such antibodies. Moreover, the application discloses a method of treating lung cancer with antibodies directed against DAF.Type: GrantFiled: May 28, 2003Date of Patent: October 30, 2007Assignee: Genentech, Inc.Inventors: Paul J. Carter, John B. Ridgway
-
Patent number: 7285267Abstract: The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6? & -6? proteins. TNFR-6? & -6? polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6? & -6? activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: August 24, 2001Date of Patent: October 23, 2007Assignee: Human Genome Sciences, Inc.Inventors: Reiner L. Gentz, Reinhard Ebner, Guo-Liang Yu, Steven M. Ruben, Jian Ni, Ping Feng
-
Patent number: 7282346Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a variety of immunohistochemical and genetic markers associated with poor cancer prognosis, and in particular those markers related to tumor invasiveness, metastasis and spread. The invention also provides methods using a predictive index for prognosis of cancer patients for metastasis, recurrence and relapse of neoplastic disease. The methods of the invention are useful for making clinical decisions on cancer treatment, surveillance and surgical intervention.Type: GrantFiled: October 16, 2001Date of Patent: October 16, 2007Assignee: Oncotech, Inc.Inventor: John Fruehauf
-
Patent number: 7282207Abstract: This invention relates generally to a multimeric polypeptide complex/antigen which may be utilized in detecting or diagnosing diseases of the uterus such as uterine cancer. Furthermore, the invention relates to methods and kits, for example, which utilize this antigen or an antibody thereto. The complex itself comprises at least one EU250 polypeptide and at least one polypeptide which may be a BU101 polypeptide and/or a TU104 polypeptide. The complex may further comprise other, as yet unknown, polypeptide sequences.Type: GrantFiled: April 13, 2000Date of Patent: October 16, 2007Assignee: Abbott LaboratoriesInventors: Tracey L. Colpitts, John C. Russell
-
Patent number: 7279294Abstract: The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.Type: GrantFiled: April 3, 2001Date of Patent: October 9, 2007Assignee: The United States of America as represented by the Secretary, Dept. of Health and Human Services, NIHInventors: Patrice J. Morin, Cheryl A. Sherman-Baust, Ellen S. Pizer, Colleen D. Hough
-
Patent number: 7276586Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 2, 2002Date of Patent: October 2, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
-
Patent number: 7276237Abstract: The present invention provides the receptors for Mob-5 (IL-24). One of the Mob-5 receptors comprises IL-22R1 and IL-20R2. Another Mob-5 receptor comprises IL-20R1 and IL-22R2. The invention also provides methods of inhibiting the Mob-5 receptor as well as methods of detecting cancer by detecting the presence of the Mob-5 receptor.Type: GrantFiled: May 9, 2005Date of Patent: October 2, 2007Assignee: Vanderbilt UniversityInventor: Peng Liang
-
Patent number: 7276372Abstract: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.Type: GrantFiled: December 19, 2003Date of Patent: October 2, 2007Assignee: PDL Biopharma, Inc.Inventors: Debbie Law, Qi Wang, Robert DuBridge, Vinay Bhaskar
-
Patent number: 7273924Abstract: A specific binding member is specific for and binds directly to the ED—B oncofoetal domain of fibronectin (FN).Type: GrantFiled: May 23, 1997Date of Patent: September 25, 2007Assignee: Philogen S.p.A.Inventors: Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
-
Patent number: 7273926Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: April 24, 2002Date of Patent: September 25, 2007Assignee: Genentech, Inc.Inventors: Kevin P. Baker, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
-
Patent number: 7268219Abstract: A complex comprising an HLA Class 1 molecule and attaching means for selectively attaching the HLA class 1 molecule to a target cell is disclosed, and a method is provided for producing or enhancing an immunological response against a target cell, by attaching said complex to the target cell. Where the target is a diseased, foreign or malignant cell, this method may be used to promote the lysis of the targeted cell by T cells in the immune system. Where the target cell is an antigen presenting cell, this method may be used to promote the proliferation of specific T cell clones. The invention is of potential use in the prevention and treatment of malignant diseases including cancer and leukemia, infectious diseases including viral infections such as HIV, bacterial infections including tuberculosis, and parasitic infections including malaria.Type: GrantFiled: November 28, 2000Date of Patent: September 11, 2007Assignee: Alexis Biotech LimitedInventor: Philip Michael Savage
-
Patent number: 7262276Abstract: The present invention provides an anti-ovarian cancer bispecific antibody. Said antibody includes two polypeptide domains connected by a polypeptide linker, one is anti-ovarian cancer antibody, or its Fab fragment, single complementarity determining region (CDR) antibody or single chain Fv (scFv) and the other is anti-CD3 antibody, or its Fab fragment, single CDR antibody or scFv. The present invention also provides DNA sequences encoding said antibody, an expression vector containing said DNA sequence, and a host cell containing said expression vector.Type: GrantFiled: May 23, 2002Date of Patent: August 28, 2007Assignee: Beijing ABT Genetic Engineering Technology Co. Ltd.Inventors: Hualiang Huang, Xin Jiang, Min Fang, Xiaocong Yu, Jie Feng, Ping Zhou, Qing Lin
-
Patent number: 7247710Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 6, 2002Date of Patent: July 24, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
-
Patent number: 7247303Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: GrantFiled: August 15, 2003Date of Patent: July 24, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran
-
Patent number: 7244574Abstract: A monoclonal antibody having inhibitory activity on blood coagulation reactions, which reacts with prothrombin forming a complex with phosphatidylserine but does not react with prothrombin not forming a complex with phosphatidylserine; and a method for measuring inhibitory activity of test plasma on blood coagulation reactions, which comprises the steps of (1) measuring inhibitory activity of the test plasma on the blood coagulation reactions and inhibitory activity of this on the blood coagulation reactions, and (2) comparing the inhibitory activity of the test plasma with the inhibitory activity of this antibody.Type: GrantFiled: March 19, 2002Date of Patent: July 17, 2007Assignee: Eisai Co., LtdInventors: Tatsuya Atsumi, Takao Koike
-
Patent number: 7244826Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: February 12, 1999Date of Patent: July 17, 2007Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Patent number: 7238786Abstract: This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-associated antibody designated PAM4. The invention further relates to chimeric PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.Type: GrantFiled: June 16, 2003Date of Patent: July 3, 2007Assignee: Immunomedics, Inc.Inventors: David V. Gold, David M. Goldenberg, Hans J. Hansen
-
Patent number: 7238787Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 7, 2002Date of Patent: July 3, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
-
Patent number: 7235642Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: September 11, 2002Date of Patent: June 26, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Austin L. Gurney, Jean Philippe Stephan, William I. Wood
-
Patent number: 7232889Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 1, 2002Date of Patent: June 19, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
-
Patent number: 7232888Abstract: The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.Type: GrantFiled: July 1, 2003Date of Patent: June 19, 2007Assignee: Massachusetts Institute of TechnologyInventors: Richard J. H. Begent, Kerry Ann Chester, Christilyn P. Graff, K. Dane Wittrup
-
Patent number: 7232887Abstract: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.Type: GrantFiled: October 15, 2003Date of Patent: June 19, 2007Assignee: United States of America, represented by the Secretary, Department of Health and Human ServicesInventors: Yutaka Kawakami, Steven A. Rosenberg
-
Patent number: 7230084Abstract: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.Type: GrantFiled: September 30, 2002Date of Patent: June 12, 2007Assignee: Immunomedics, Inc.Inventor: Hans J. Hansen
-
Patent number: 7226596Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contributes to tumorigenesis. Accordingly, the ADAM8 protein encoded by the amplified gene is a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and acts as a predictor of the prognosis of tumor treatment.Type: GrantFiled: August 22, 2002Date of Patent: June 5, 2007Assignee: Genentech, Inc.Inventors: Sarah C. Bodary, Karen L. Fisher
-
Patent number: 7226750Abstract: The present invention is directed to cell surface antigenes found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable of being used for therapeutic, screening, diagnostic and cell purification purposes. A representative and exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to a surface antigen that is expressed on multiple myeloma cells and to a surface antigen that is expressed on ovarian cancer cells. The function of this monoclonal antibody both in vivo and in vitro is demonstrated.Type: GrantFiled: August 8, 2000Date of Patent: June 5, 2007Assignee: Molecular Discoveries, Inc.Inventor: Cohava Gelber
-
Patent number: 7220841Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 3, 2002Date of Patent: May 22, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
-
Patent number: RE39760Abstract: Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse/humans chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunodiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.Type: GrantFiled: August 4, 2000Date of Patent: August 7, 2007Assignee: International Bio-Immune Systems Inc.Inventors: Kwong Y. Tsang, Myron Arlen